Answers are grounded in this paper and cite their sources.
Targeting Fyn can reverse memory deficits found in AD mouse models, and rescue synapse density loss characteristic of the disease. Thus, AZD0530 is a promising candidate to test as a potential therapy for AD.
No takes yet. Share an insight, caveat, or question.
Kaufman et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: